TL;DR
Get workout gear delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
Neuromod Devices appointed Joe Ghiz as chief commercial officer and Shannon Basham as vice president of channel development, the Dublin-based company announced Oct. 1, 2026. The hires support its effort to expand access to Lenire, its tinnitus treatment device; the company has not disclosed specific sales targets or a timetable for expansion.
Neuromod Devices appointed Joe Ghiz as chief commercial officer and Shannon Basham as vice president of channel development, the Dublin-based medical technology company announced Oct. 1, 2026. The appointments put new leaders in charge of global commercial work and channel development as Neuromod seeks to broaden access to Lenire, its tinnitus treatment device.
Ghiz will lead Neuromod’s global commercial function, according to the announcement. The company said it is working to position Lenire as a standard of care for tinnitus in ear, nose and throat (ENT) and audiology practices. That is Neuromod’s stated ambition; the announcement did not provide a timeline, sales goals, or details of how the company will measure progress toward it.
Ghiz joins from Align Technology, the company behind Invisalign, where he served as general manager of sales and held other global commercial leadership roles. His earlier experience includes more than a decade at Johnson & Johnson Vision Care, in sales, marketing and business development positions. Neuromod CEO Dr. Ross O’Neill cited Ghiz’s commercial experience as the company prepares to scale its business.
Basham brings more than 20 years in hearing care. Most recently, she was senior director of audiology for Sonova Group in the United States, serving as the market-facing head of audiology for its Phonak and Unitron wholesale businesses. She led strategy for audiology and clinical education. Earlier, she spent a decade as Phonak’s director of clinical training, overseeing education programs, and worked at Insound Medical as clinical training manager during the commercialization and scaling of the Lyric hearing aid.
Commercial Leadership for Lenire
The appointments fill two senior commercial roles at a company seeking wider clinical and patient access for a specialized tinnitus device. Ghiz’s remit is global commercial leadership, while Basham’s title focuses on channel development and her background centers on audiology, clinician education and hearing-care businesses. Their experience aligns with Neuromod’s stated aim of reaching more clinicians, though the company has not described specific channel agreements, geographic priorities or changes to how Lenire is prescribed.
For clinicians and patients, any effect will depend on how the company translates the appointments into availability and awareness. Lenire is not described as an over-the-counter product: Neuromod says it is prescribed after an audiological examination by an ENT or audiologist, with treatment completed at home. The executive announcement itself does not change the device’s prescribing process or establish new evidence about its effectiveness.
As an affiliate, we earn on qualifying purchases.
Lenire’s Existing Market Footprint
Neuromod describes Lenire as a non-invasive bimodal neuromodulation device that pairs audio stimulation with stimulation delivered to the surface of the tongue through a proprietary component called Tonguetip. The company says patients use it at home after a clinician’s examination. Its description provides product context, but the appointments announcement does not report new clinical findings.
According to the source material, Lenire has CE-mark certification and received a US Food and Drug Administration De Novo approval grant. Neuromod says the device is available in the United States, Canada, Europe and Australia, and is also a treatment option through the US Veterans Affairs system. The company operates in Ireland and North America. These existing regulatory and market details help explain the global scope of the commercial roles; the announcement does not say that either appointment expands the device’s authorized uses or availability.
““I look forward to working with Neuromod’s leadership team to deliver the commercial strategy required to reach more clinicians.””
— Joe Ghiz, Neuromod chief commercial officer
As an affiliate, we earn on qualifying purchases.
Expansion Plans Remain Unspecified
The announcement does not state when Ghiz and Basham began their roles, how many staff or markets they will oversee, or whether Neuromod plans to enter additional countries. It also does not disclose commercial targets, channel partnerships, budgets or a timetable for making Lenire more widely available. No new regulatory decision or clinical study result was announced alongside the appointments.
Neuromod and its executives describe Lenire’s potential and its position in tinnitus care, but those statements are company views, not independently established outcomes in this announcement. The source material does not provide underlying data for the CEO’s reference to the number of people affected by tinnitus or Ghiz’s statement about patients helped. How the company will assess whether Lenire becomes more commonly used in ENT and audiology practices remains unclear.
As an affiliate, we earn on qualifying purchases.
Implementation Will Show the Strategy
The next development to watch is how Neuromod sets out its commercial priorities under Ghiz and its channel approach under Basham. The company may provide more detail through future announcements about clinician outreach, distribution, geographic availability or business performance, but no next milestone was specified in the Oct. 1 announcement.
For now, the confirmed change is at the leadership level. Further information would be needed to determine whether the appointments lead to new markets, broader clinician adoption or changes in patient access. Neuromod’s stated goal is to scale access to Lenire; the practical results and timing remain to be seen.
As an affiliate, we earn on qualifying purchases.
Key Questions
Who did Neuromod Devices appoint?
Neuromod appointed Joe Ghiz as chief commercial officer and Shannon Basham as vice president of channel development. The company announced the appointments on Oct. 1, 2026.
What will Ghiz and Basham do?
Ghiz will lead Neuromod’s global commercial function. Basham will lead channel development; her prior work includes audiology strategy and clinical education at Sonova and Phonak. The company has not released detailed objectives or targets for either role.
What is Lenire?
Neuromod describes Lenire as a non-invasive device for tinnitus that combines audio stimulation with stimulation to the tongue’s surface. It is prescribed by an ENT or audiologist after an audiological examination, with treatment completed at home, according to the company.
Did Neuromod announce a new approval or clinical result?
No. The announcement concerned two executive appointments. The source material notes Lenire’s existing CE-mark certification and US FDA De Novo approval grant, but reports no new regulatory decision or clinical study result.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
